# Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia

> **NCT01163838** · PHASE1 · WITHDRAWN · sponsor: **Pfizer**

## Conditions studied

- Hypercholesterolemia
- Dyslipidemia

## Interventions

- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** 1 mg/kg every 2 weeks
- **BIOLOGICAL:** 2 mg/kg every 4 weeks
- **BIOLOGICAL:** 4 mg/kg every 4 weeks
- **BIOLOGICAL:** 4 mg/kg every 8 weeks
- **BIOLOGICAL:** 8 mg/kg every 8 weeks
- **BIOLOGICAL:** 12 mg/kg every 8 weeks

## Key facts

- **NCT ID:** NCT01163838
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-08
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study was redesigned based on FDA feedback.
- **Last updated:** 2015-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01163838

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01163838, "Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT01163838. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*